Literature DB >> 30077942

Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature.

Connor J Kinslow1, Steven D Shapiro2, Michael F Grunebaum3, Eliza C Miller4.   

Abstract

Concurrent use of modafinil or armodafinil with monoamine oxidase inhibitors (MAOIs) is contraindicated due to a theoretical risk of drug synergism and acute hypertensive episodes. However, few data are available to substantiate that risk, and several case studies have suggested that the combination is safe. To our knowledge, we present the first case of a patient treated concurrently with armodafinil and tranylcypromine. The patient developed an acute hypertensive crisis with severe headache, nausea, blurry vision, and neck stiffness. Her symptoms corresponded with the predicted pharmacokinetic and pharmacodynamic response. She was also taking brexpiprazole, which could have contributed to her underlying symptoms. However, limited data suggest that the single combination of brexpiprazole with armodafinil or MAOIs would be safe. Upon review of the literature, two out of seven patients, including our own, treated concurrently with modafinil or armodafinil and an MAOI developed an adverse reaction. Physicians should exercise caution if using these classes of drugs together.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30077942      PMCID: PMC6446082          DOI: 10.1016/j.jns.2018.07.023

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Modafinil augmentation of phenelzine for residual fatigue in dysthymia.

Authors:  Adam Keller Ashton
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

2.  Acute chorea and hyperthermia after concurrent use of modafinil and tranylcypromine.

Authors:  Michal Vytopil; Ram Mani; Ashish Adlakha; Jay-Jiguang Zhu
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

3.  Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.

Authors:  Mona Darwish; Mary Kirby; Denise M D'Andrea; Ronghua Yang; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Ther       Date:  2010-11       Impact factor: 3.393

Review 4.  Reversible cerebral vasoconstriction syndrome: a comprehensive update.

Authors:  Ali Mehdi; Rula A Hajj-Ali
Journal:  Curr Pain Headache Rep       Date:  2014-09

Review 5.  Modafinil: a review of neurochemical actions and effects on cognition.

Authors:  Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

6.  Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.

Authors:  William Eric Clemons; Eugene Makela; John Young
Journal:  Sleep Med       Date:  2004-09       Impact factor: 3.492

7.  Morphine is an arteriolar vasodilator in man.

Authors:  Reza Afshari; Simon R J Maxwell; David J Webb; D Nicholas Bateman
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

8.  Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Authors:  Michael E Thase; James M Youakim; Aleksandar Skuban; Mary Hobart; Carole Augustine; Peter Zhang; Robert D McQuade; William H Carson; Margaretta Nyilas; Raymond Sanchez; Hans Eriksson
Journal:  J Clin Psychiatry       Date:  2015-09       Impact factor: 4.384

9.  Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.

Authors:  Michael E Thase; James M Youakim; Aleksandar Skuban; Mary Hobart; Peter Zhang; Robert D McQuade; Margaretta Nyilas; William H Carson; Raymond Sanchez; Hans Eriksson
Journal:  J Clin Psychiatry       Date:  2015-09       Impact factor: 4.384

10.  Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects.

Authors:  A G Mallinger; D J Edwards; J M Himmelhoch; S Knopf; J Ehler
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.